Checkpoint Therapeutics
Waltham
About Checkpoint Therapeutics
Checkpoint Therapeutics mainly engages in advancing the development of cancer immunotherapy and targeted oncology treatments. It is dedicated to developing and bringing cancer therapies to market faster and actively pursuing product purchases, in-licensing, and co-development opportunities that align with its areas of expertise. The company provides a streamlined approach that lowers risk and accelerates the development and commercialization of oncology drugs, ensuring more patients, payors, and providers benefit from effective and affordable treatment options.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $22.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jul 2024)
- Ticker: nasdaq:CKPT
- Website: checkpointtx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Oncology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/checkpoint-therapeutics-75237 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.